DanielHalperinMD

Endocrine Cancer, Gastrointestinal Cancer, Hematologic Oncology

Vice Chair for Clinical Affairs, Associate Professor, Hematology and Medical Oncology, Winship Cancer Institute of Emory University

Join to view full profile

Dr. Halperin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Halperin's full profile

Already have an account?

Office
36 Linden Ave
Atlanta, GA 30308
Phone+1 404-778-1900

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
Brigham and Women's HospitalResidency, Internal Medicine, 2010 - 2012
Brigham and Women's HospitalInternship, Internal Medicine, 2009 - 2010
Weill Cornell MedicineClass of 2009

Certifications & Licensure

FL State Medical License 2021 - Present
GA State Medical License 2023 - 2026
TX State Medical License 2014 - 2026
AZ State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
WA State Medical License 2023 - 2025
AL State Medical License 2023 - 2024
LA State Medical License 2023 - 2024
TN State Medical License 2023 - 2024
MA State Medical License 2009 - 2012
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

Career Development Award American Society of Clinical Oncology, 2018
Waun Ki Hong Award in Clinical Investigation MD Anderson Cancer Center, 2015
Travel Award North American Neuroendocrine Tumor Society, 2014
Resident Recognition Award Harvard Medical School, 2014
Kaufman Memorial Book Award Phyllis Jen Center for Primary Care, Brigham and Women's Hospital, 2012
Coryell Prize Weill Cornell Medical College, 2009
Research Training Fellowship for Medical Students Howard Hughes Medical Institute, 2007
Robert C. Byrd Merit Scholarship 2000-2004
Research Experience for Undergraduates Scholarship National Science Foundation, 2002
Join now to see all

Clinical Trials

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Start of enrollment: 2016 Dec 08
Completed
Phase 1, Phase 2
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) Start of enrollment: 2017 Feb 14
Completed
Phase 2
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Start of enrollment: 2017 Mar 03
Active, not recruiting
Phase 2
Chromogranin A as Blood Marker in Cancer Patients Start of enrollment: 2019 Jan 29
Completed
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET Start of enrollment: 2020 Jan 22
Active, not recruiting
Phase 3
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Start of enrollment: 2022 Mar 24
Active, not recruiting
Phase 3
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE Start of enrollment: 2021 Dec 21
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

2117 citations
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Arvind Dasari, Chan Shen, Daniel M. Halperin, Bo Zhao, Shouhao Zhou
JAMA Oncology. 2017-10-01
269 citations
Neuroendocrine and adrenal tumors, version 2.2021
Manisha H. Shah, Whitney S. Goldner, Al B. Benson, Emily K. Bergsland, Lawrence S. Blaszkowsky
Journal of the National Comprehensive Cancer Network. 2021-07-28
31 citations
Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Kanwal Pratap Singh Raghav, Suyu Liu, Michael J. Overman, Anneleis Willett, Mark Knafl
Cancer Discovery. 2021-07-14

Abstracts/Posters

A prospective, multi-institutional phase II study pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumors.
Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH, NANETS: North American Neuroendocrine Tumor Society Annual Meeting, Nashville, TN, USA, 10/6/2014
Clinical Presentation and Outcomes in Patients with Advanced Pheochromcytoma/Paraganglioma: Evidence of Temozolomide Efficacy
Halperin DM, Brais L, Ramaiya NH, Kulke MH, ASCO Annual Meeting, Chicago, IL, USA, 6/2014
A phase I study of the anti-IGF-1R monoclonal antibody, IMC-A12, and everolimus in well-differentiated neuroendocrine tumors
Dasari A, Phan AT, Gupta S, Hess KR, Culotta KS, Rashid A, Yeung SJ, Chen HX, Dong M, Halperin DM, Subbiah IM, Meric-Bernstam F, Yao JC, ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 1/1/2014
Assessing pretest probability in phase II trials: One step back before two steps forward
Halperin DM, Dagohoy C, Lee JJ, Yao JC, ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 1/2014
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.
Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff P, NANETS: North American Neuroendocrine Tumor Society Annual Meeting, Charleston, SC, USA, 10/2013
Predictive value of phase II clinical trials in pancreatic cancer: Rethinking the road to progress.
Halperin DM, Lee JJ, Yao JC, ASCO Annual Meeting, Chicago, IL, USA, 6/2013
Join now to see all

Lectures

A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs).
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020

Press Mentions

10 Things to Know About Neuroendocrine TumorsFebruary 23rd, 2024
MD Anderson Research Highlights for April 13, 2022April 13th, 2022
Combination Bevacizumab plus Atezolizumab May Effectively Treat Some Neuroendocrine TumorsApril 13th, 2022
Join now to see all

Committees

Member, MD Anderson House Staff Senate 2014 - 2015
Member, Brigham and Women's Hospital Clinicopathologic Conference Committee 2011 - 2012
Member, Brigham and Women's Hospital Department of Medicine Educational Committee 2011 - 2012
Member, Weill Cornell Medical College Committee on Admissions 2008 - 2009